

TABLE 91 Summary results for the direct meta-analysis and results of the mixed-treatment comparison (HR, 95% CI) 2-year survival for trials comparing chemotherapy vs chemotherapy in population 1: population with squamous disease

Reference treatment vs comparator	Direct meta-analysis 1 (n = 16), HR (95% CI)	Mixed-treatment comparison 1 (n = 16), HR (95% CI)	Mixed-treatment comparison A (n = 15), HR (95% CI)	Mixed-treatment comparison B (n = 16), HR (95% CI)	Mixed-treatment comparison C (n = 16), HR (95% CI)
GEM + PLAT vs VNB + PLAT ^{43,45,49,50,54,55,57,58}	0.89 (0.66 to 1.21)	0.84 (0.65 to 1.11)	0.84 (0.65 to 1.11)	0.84 (0.65 to 1.11)	0.85 (0.67 to 1.1)
GEM + PLAT vs PAX + PLAT ^{43,46,47,56,57,60}	1.06 (0.78 to 1.46)	1.04 (0.81 to 1.37)	1.04 (0.81 to 1.38)	1.03 (0.79 to 1.36)	1.04 (0.82 to 1.34)
GEM + PLAT vs DOC + PLAT ⁴⁷	0.86 (0.55 to 1.34)	0.95 (0.63 to 1.4)	0.96 (0.62 to 1.42)	0.96 (0.62 to 1.41)	0.89 (0.61 to 1.29)
VNB + PLAT vs PAX + PLAT ^{43,48,51,57}	0.82 (0.53 to 1.28)	1.24 (0.92 to 1.66)	1.24 (0.92 to 1.67)	1.23 (0.9 to 1.65)	1.23 (0.93 to 1.62)
VNB + PLAT vs DOC + PLAT ^{44,53,59}	0.97 (0.56 to 1.68)	1.14 (0.76 to 1.6)	1.14 (0.75 to 1.62)	1.14 (0.76 to 1.61)	1.05 (0.73 to 1.46)
PAX + PLAT vs DOC + PLAT ⁴⁷	1.0 (0.79 to 1.59) ^a	0.92 (0.58 to 1.37)	0.92 (0.58 to 1.4)	0.93 (0.59 to 1.41)	0.86 (0.56 to 1.27)

a Direct evidence available. Direct meta-analysis A and mixed-treatment comparison A: sensitivity analysis excluding Chen *et al.*⁵² (<24 months follow-up time) and Tan *et al.*⁵⁹ (used six cycles of chemotherapy). Direct meta-analysis B and mixed-treatment comparison B: sensitivity analysis using data from PAX + CIS instead of PAX + CARB from the Schiller *et al.* trial.⁴⁷ Direct meta-analysis C and mixed-treatment comparison C: sensitivity analysis using data from DOC + CARB instead of DOC + CIS from the Fossella *et al.* trial.⁴⁴ Direct meta-analysis D and mixed-treatment comparison D: sensitivity analysis excluding Tan *et al.*⁵⁹ (used six cycles of chemotherapy). Direct meta-analysis E and mixed-treatment comparison E: sensitivity analysis excluding Chen *et al.*⁵² (<24 months follow-up time). This affects VNB + PLAT vs DOC + PLAT pair-wise comparison.

A HR > 1 favours the reference treatment and a HR < 1 favours the comparator treatment.